Thalidomide therapy for aggressive histiocytic lesions in the pediatric population.
Aggressive histiocytic lesions are uncommon in the pediatric population. These neoplasms occur in isolation or after therapy for other types of hematopoietic malignancy such as T-cell acute lymphoblastic leukemia. The etiology of these lesions is poorly understood, and no definitive standard of care has been established for patients with these diagnoses. Here, we report the success of thalidomide treatment for 2 subtypes of histiocytic proliferation--metastatic histiocytic sarcoma and extracutaneous juvenile xanthogranuloma--in pediatric patients. Our findings highlight the importance of considering thalidomide therapy in this unique and difficult to treat patient population.
Departments of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.
Kelly M
KM
Bailey
Valerie P
VP
Castle
Jennifer M
JM
Hummel
Morand
M
Piert
Judith
J
Moyer
Linda M
LM
McAllister-Lucas
D000293:Adolescent; D002648:Child; D005260:Female; D054747:Histiocytic Sarcoma / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008824:Michigan / Q000453:epidemiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000628:therapy; D011379:Prognosis; D013792:Thalidomide / Q000627:therapeutic use*; D014972:Xanthogranuloma, Juvenile / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
D007166:Immunosuppressive Agents; D013792:Thalidomide